15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

2020 ◽  
Vol 83 (6) ◽  
pp. AB41
Author(s):  
Gil Yosipovitch ◽  
Thomas Bieber ◽  
Linda Stein Gold ◽  
Shawn Kwatra ◽  
Svitlana Tatulych ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document